Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

被引：4

作者：

Harrison, Claire ^{[1
]}

Nangalia, Jyoti ^{[2
,3
,4
]}

Boucher, Rebecca H. ^{[5
]}

Jackson, Aimee ^{[5
]}

Yap, Christina ^{[5
,6
]}

O'Sullivan, Jennifer ^{[7
,8
,9
]}

Fox, Sonia ^{[10
]}

Ailts, Isaak ^{[11
]}

Dueck, Amylou C. ^{[12
]}

Geyer, Holly L. ^{[11
]}

Mesa, Ruben ^{[13
]}

Dunn, William ^{[4
]}

Nadezhdin, Eugene ^{[3
]}

Curto-Garcia, Natalia ^{[7
]}

Green, Anna ^{[14
]}

Wilkins, Bridget ^{[7
]}

Coppell, Jason ^{[15
]}

Laurie, John ^{[16
]}

Garg, Mamta ^{[17
]}

Ewing, Joanne ^{[18
]}

Knapper, Steve ^{[19
]}

Crowe, Josephine ^{[20
]}

Koutsavlis, Ioannis ^{[21
]}

Godfrey, Anna L. ^{[22
]}

Arami, Siamak ^{[23
]}

Drummond, Mark W. ^{[24
]}

Byrne, Jennifer ^{[22
]}

Clark, Fiona J. ^{[25
,26
]}

Mead-Harvey, Carolyn ^{[12
]}

Baxter, Joanna E. ^{[27
]}

McMullin, Mary Frances ^{[28
]}

Mead, Adam J. ^{[8
,9
,29
]}

机构：

[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England

[2] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

[3] Wellcome Sanger Inst Hinxton, Hinxton, Cambs, England

[4] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England

[5] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England

[6] Inst Canc Res, Clin Trials & Stat Unit, London, England

[7] Guys & St Thomas NHS Fdn Trust, London, England

[8] Univ Oxford, Med Res Council Weatherall Inst Mol Med, Oxford, England

[9] Univ Oxford, NIHR Biomed Res Ctr, Oxford, England

[10] Univ Birmingham, Clin Trials Unit, Canc Res UK, Birmingham, W Midlands, England

[11] Mayo Clin, Dept Internal Med, Scottsdale, AZ USA

[12] Mayo Clin, Dept Quantitat Hlth Sci, Scottsdale, AZ USA

[13] UT Hlth San Antonio, Mays Canc Ctr, San Antonio, TX USA

[14] Guys & St ThomasNHS Fdn Trust, Dept Histopathol, London, England

[15] Royal Devon & Exeter Hosp, Exeter, Devon, England

[16] Worthing Dist Hosp, Worthing, England

[17] Univ Hosp Leicester, Leicester, Leics, England

[18] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[19] Cardiff Univ, Sch Med, Cardiff, Wales

[20] Royal United Hosp, Bath, Avon, England

[21] Western Gen Hosp, Lothian Hlth Board, Edinburgh, Midlothian, Scotland

[22] Cambridge Univ Hosp NHS Fdn Trust, Dept Clin Haematol, Cambridge, England

[23] London North West Univ Healthcare NHS Trust, Harrow, Middx, England

[24] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[25] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England

[26] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Cambridge, England

[27] Cambridge Blood & Stem Cell Biobank NHS BT Cambri, Haematol, Cambridge, England

[28] Queens Univ, Ctr Med Educ, Belfast, Antrim, North Ireland

[29] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Canc & Haematol Ctr, Oxford, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157273

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1781 / 1783

页数：3

共 50 条

[1] Ruxolitinib versus best available therapy for PV intolerant or resistant to Hydroxycarbamide a randomised trial
Harrison, Claire
Nangalia, Jyoti
Boucher, Rebecca
Jackson, Aimee
Yap, Christina
O'Sullivan, Jennifer
Fox, Sonia
Ailts, Isaak
Dueck, Amylou
Geyer, Holly
Mesa, Ruben
Dunn, William
Nadezhdin, Eugene
Curto-Garcia, Natalia
Green, Anna
Wilkins, Bridget
Coppell, Jason
Laurie, John
Garg, Mamta
Ewing, Joanne
Knapper, Steven
Crowe, Josephine
Chen, Frederick
Koutsavlis, Ioannis
Godfrey, Anna
Arami, Siamak
Drummond, Mark
Byrne, Jennifer
Clark, Fiona
Mead-Harvey, Carolyn
Baxter, Elizabeth
McMullin, Mary Frances
Mead, Adam
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 88 - 88
[2] Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Harrison, Claire N.
Nangalia, Jyoti
Boucher, Rebecca
Jackson, Aimee
Yap, Christina
O'Sullivan, Jennifer
Fox, Sonia
Ailts, Isaak
Dueck, Amylou C.
Geyer, Holly L.
Mesa, Ruben A.
Dunn, William G.
Nadezhdin, Eugene
Curto-Garcia, Natalia
Green, Anna
Wilkins, Bridget
Coppell, Jason
Laurie, John
Garg, Mamta
Ewing, Joanne
Knapper, Steven
Crowe, Josephine
Chen, Frederick
Koutsavlis, Ioannis
Godfrey, Anna
Arami, Siamak
Drummond, Mark
Byrne, Jennifer
Clark, Fiona
Mead-Harvey, Carolyn
Baxter, Elizabeth Joanna
McMullin, Mary Frances
Mead, Adam J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (19) : 3534 - +
[3] Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Harrison, Claire N.
Mead, Adam J.
Panchal, Anesh
Fox, Sonia
Yap, Christina
Gbandi, Emmanouela
Houlton, Aimee
Alimam, Samah
Ewing, Joanne
Wood, Marion
Chen, Frederick
Coppell, Jason
Panoskaltsis, Nicki
Knapper, Steven
Ali, Sahra
Hamblin, Angela
Scherber, Robyn
Dueck, Amylou C.
Cross, Nicholas C. P.
Mesa, Ruben
McMullin, Mary Frances
BLOOD, 2017, 130 (17) : 1889 - 1897
[4] RUXOLITINIB COMPARED WITH BEST AVAILABLE THERAPY FOR ESSENTIAL THROMBOCYTHAEMIA PATIENTS RESISTANT OR INTOLERANT TO HYDROXYCARBAMIDE IN MAJIC - AN INVESTIGATOR LEAD RANDOMIZED TRIAL
Harrison, C.
Mead, A.
Panchal, A.
Fox, S.
Yap, C.
Houlton, A.
Aliman, S.
Wood, M.
Chen, F.
Coppell, J.
Panoskaltsis, N.
Scherber, R.
Geyer, H.
Dueck, A.
Mesa, R.
McMullin, M. F.
HAEMATOLOGICA, 2016, 101 : 97 - 97
[5] RUXOLITINIB PROVES SUPERIOR TO BEST AVAILABLE THERAPY IN A PROSPECTIVE, RANDOMIZED, PHASE 3 STUDY (RESPONSE) IN PATIENTS WITH POLYCYTHEMIA VERA RESISTANT TO OR INTOLERANT OF HYDROXYUREA
Vannucchi, A. M.
Kiladjian, J. J.
Griesshammer, M.
Masszi, T.
Durrant, S.
Passamonti, F.
Harrison, C. N.
Pane, F.
Zachee, P.
Mesa, R.
He, S.
Jones, M. M.
Garrett, W.
Li, J.
Francillard, N.
Habr, D.
Verstovsek, S.
HAEMATOLOGICA, 2014, 99 : 790 - 790
[6] Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide
Harrison, Claire N.
Griesshammer, Martin
Miller, Carole
Masszi, Tamas
Passamonti, Francesco
Zachee, Pierre
Durrant, Simon
Pane, Fabrizio
Guglielmelli, Paola
Verstovsek, Srdan
Jones, Mark M.
Hunter, Deborah S.
Sun, William
Li, Jingjin
Khan, Mahmudul
Habr, Dany
Kiladjian, Jean-Jacques
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 (02) : 279 - 284
[7] RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with bydroxyurea (HU)- resistant/intolerant polycytheinia vera (PV) versus best available therapy (BAT).
Passamonti, Francesco
Saydam, Guray
Lim, Liberata
Khan, Mahmudul H.
Mounedji, Nadjat
Griasshammer, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[8] COST-UTILITY ANALYSIS OF RUXOLITINIB VERSUS BEST AVAILABLE THERAPY FOR THE TREATMENT OF HYDROXYUREA RESISTANT/INTOLERANT POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY IN THE UNITED STATES
Hong, S.
Veenstra, D. L.
VALUE IN HEALTH, 2020, 23 : S50 - S50
[9] JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Harrison, Claire
Kiladjian, Jean-Jacques
Al-Ali, Haifa Kathrin
Gisslinger, Heinz
Waltzman, Roger
Stalbovskaya, Viktoriya
McQuitty, Mari
Hunter, Deborah S.
Levy, Richard
Knoops, Laurent
Cervantes, Francisco
Vannucchi, Alessandro M.
Barbui, Tiziano
Barosi, Giovanni
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (09): : 787 - 798
[10] Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis A Randomized Clinical Trial
Mascarenhas, John
Hoffman, Ronald
Talpaz, Moshe
Gerds, Aaron T.
Stein, Brady
Gupta, Vikas
Szoke, Anita
Drummond, Mark
Pristupa, Alexander
Granston, Tanya
Daly, Robert
Al-Fayoumi, Suliman
Callahan, Jennifer A.
Singer, Jack W.
Gotlib, Jason
Jamieson, Catriona
Harrison, Claire
Mesa, Ruben
Verstovsek, Srdan
JAMA ONCOLOGY, 2018, 4 (05) : 652 - 659

← 1 2 3 4 5 →